GPGI Faces Securities Investigation Following Quarterly Sales Slump
A 26% drop in GPGI stock value has triggered a formal investigation by Robbins Geller Rudman & Dowd LLP. The firm is examining potential federal securities law violations after the injection molding company reported sharp declines in both its quarterly sales and core profitability metrics earlier this spring.
The scrutiny follows GPGI's May 7, 2026, financial disclosure, which revealed significant headwinds within its Husky segment. Pro forma adjusted net sales for the quarter slid to $290.8 million, a 5.2% decline from the previous year. More notably, the company’s pro forma adjusted EBITDA plummeted by 40.2% to $38 million, prompting a rapid sell-off of shares.
Robbins Geller, a firm specializing in shareholder rights litigation, is now soliciting information from investors and potential witnesses regarding the company's financial reporting. Attorneys Ken Dolitsky and Michael Albert are leading the inquiry, which seeks to determine whether the company misled shareholders prior to the earnings release. The firm has requested that those who suffered losses or possess relevant internal information contact their San Diego offices directly.
Comments (0)
No comments yet. Be the first!